SCHEMBL17448774

SCHEMBL17448774

Cc1ccc(COC(C)c2ccc(C)cc2C)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
SLC6A2 P23975 2/20 0.35
TRPA1 O75762 1/20 0.35
LMNA P02545 1/20 0.35
CHRM1 P11229 1/20 0.35
ADRA1A P35348 1/20 0.35
HTR2B P41595 1/20 0.35
PYCR1 P32322 1/20 0.35
SRC P12931 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
CASP1 P29466 1/20 0.34
HBB P68871 1/20 0.34
KMT2A Q03164 1/20 0.34
SLC6A4 P31645 1/20 0.34
CASR P41180 1/20 0.33
NR3C1 P04150 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17448776 0.83 AGXT (0.41) KDM4EALDH1A1SLC6A2TRPA1LMNA
SCHEMBL5669450 0.80 SMN1; SMN2 (0.39) KDM4EALDH1A1SLC6A2TRPA1LMNA
SCHEMBL14887942 0.80 KDM4E (0.38) KDM4EALDH1A1SLC6A2PYCR1SRC
SCHEMBL9070286 0.77 KDM4E (0.44) KDM4EALDH1A1SLC6A2PYCR1MEN1
SCHEMBL683175 0.77 KDM4E (0.47) KDM4EALDH1A1SLC6A2PYCR1MEN1
SCHEMBL8750365 0.75 TRPA1 (0.43) KDM4EALDH1A1SLC6A2TRPA1LMNA
SCHEMBL8750414 0.74 TRPA1 (0.42) KDM4EALDH1A1SLC6A2TRPA1LMNA
SCHEMBL30618212 0.73 ALDH1A1 (0.44) KDM4EALDH1A1SLC6A2LMNAPYCR1
SCHEMBL8516081 0.73 ALDH1A1 (0.44) KDM4EALDH1A1SLC6A2LMNAPYCR1
SCHEMBL15012476 0.73 ALDH1A1 (0.44) KDM4EALDH1A1LMNAPYCR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160015707-A1 METHOD OF PROMOTING REMYELINATION UNIV CASE WESTERN RESERVE (US) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015707-A1 METHOD OF PROMOTING REMYELINATION CHAT, PMP22, MAG KDM4E 1491/4885ALDH1A1 761/4885SLC6A2 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.